Hepatitis B virus is transmitted through three main routes: blood, sexual contact, and mother-to-child transmission. Mother-to-child transmission is mainly intrauterine and can occur during pregnancy, but the incidence is less than 10%. Mother-to-child transmission occurs more often during or after delivery, when the child is exposed to the blood and lotion of the HBV-positive mother. This is the main cause of hepatitis B virus infection in our country in the past. Since it is not a genetic disease, it can be blocked by the hepatitis B vaccine and hepatitis B immunoglobulin. Mother-to-child transmission can be immune blocked by drugs, in fact, the first issue that should be considered is whether the mother is in the virus carriage or immune clearance period, if in the immune clearance period we should consider whether the mother-to-be can withstand the pregnancy. When liver disease is aggravated, pregnant women are prone to complications. For this reason, it is important for people with hepatitis B virus to be cautious when choosing whether or not to become pregnant, and not to blindly conceive with the mindset of trying. The liver of hepatitis B virus carriers has no or only minor lesions despite viral replication, and pregnancy has little effect on the normal liver of pregnant women. If the liver function series is always normal in long-term follow-up examinations and the ultrasound examination does not suggest cirrhosis, pregnancy can be considered. If the hepatitis B virus is in the active stage, the patient has abnormal liver function, self-conscious fatigue, loss of appetite, abdominal distension, etc., and the inflammatory phase of the liver must be given antiviral treatment to stabilize the disease before considering childbirth, otherwise the disease may easily aggravate or even endanger the life of the pregnant woman. 2010 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B recommends that women of childbearing age who are in the active stage of the hepatitis B virus must first undergo antiviral treatment and take reliable measures to prevent pregnancy during the treatment period. The 2010 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B recommends that women of childbearing age who are active with hepatitis B must first receive antiviral therapy and take reliable measures to prevent pregnancy during treatment. There are currently two classes of antiviral therapy drugs: nucleoside (acid) analogs and interferon analogs. Since interferon is used for the treatment of chronic hepatitis B for a definite duration, usually about 1 year, it can be used 3-6 months after the end of treatment to stabilize the disease before pregnancy; while the duration of oral nucleoside (acid) class antiviral drugs is uncertain, and some patients need long-term treatment, patients of childbearing age should not only be concerned about drug resistance when choosing nucleoside (acid) class treatment but also be alert to the pregnancy safety of nucleoside (acid) class drugs. The safety of nucleoside (acid) drugs in pregnancy is also a concern. Therefore, for patients of childbearing age with chronic hepatitis B, antiviral therapy with either telbivudine or tenofovir may be indicated.